ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

ORIC Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

A number of other equities research analysts have also weighed in on ORIC. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Wednesday, August 14th. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, August 12th. Oppenheimer decreased their price target on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Finally, Stifel Nicolaus assumed coverage on shares of ORIC Pharmaceuticals in a report on Friday, September 6th. They issued a “buy” rating and a $20.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $18.00.

ORIC Pharmaceuticals Price Performance

Shares of ORIC stock opened at $9.96 on Monday. The stock’s 50 day simple moving average is $9.77 and its two-hundred day simple moving average is $10.15. ORIC Pharmaceuticals has a 1 year low of $5.27 and a 1 year high of $16.65. The company has a market cap of $671.52 million, a PE ratio of -5.53 and a beta of 1.12.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Equities research analysts expect that ORIC Pharmaceuticals will post -1.78 EPS for the current year.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. boosted its stake in ORIC Pharmaceuticals by 0.9% during the 4th quarter. Victory Capital Management Inc. now owns 126,030 shares of the company’s stock worth $1,159,000 after purchasing an additional 1,180 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ORIC Pharmaceuticals by 162.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after buying an additional 3,188 shares during the period. Profund Advisors LLC lifted its position in ORIC Pharmaceuticals by 23.6% in the second quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after buying an additional 4,175 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in ORIC Pharmaceuticals by 104.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,922 shares of the company’s stock worth $178,000 after buying an additional 6,617 shares during the period. Finally, Quest Partners LLC increased its position in shares of ORIC Pharmaceuticals by 253.2% during the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after acquiring an additional 7,440 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.